Suppr超能文献

无标记血浆蛋白质组学鉴定出触珠蛋白相关蛋白为特发性肺纤维化的候选标志物,并发现补体和氧化途径失调。

Label-free plasma proteomics identifies haptoglobin-related protein as candidate marker of idiopathic pulmonary fibrosis and dysregulation of complement and oxidative pathways.

机构信息

Transplantation Laboratory, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

HUSLAB, Helsinki University Hospital, Helsinki, Finland.

出版信息

Sci Rep. 2020 May 8;10(1):7787. doi: 10.1038/s41598-020-64759-x.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a lung parenchymal disease of unknown cause usually occurring in older adults. It is a chronic and progressive condition with poor prognosis and diagnosis is largely clinical. Currently, there exist few biomarkers that can predict patient outcome or response to therapies. Together with lack of markers, the need for novel markers for the detection and monitoring of IPF, is paramount. We have performed label-free plasma proteomics of thirty six individuals, 17 of which had confirmed IPF. Proteomics data was analyzed by volcano plot, hierarchical clustering, Partial-least square discriminant analysis (PLS-DA) and Ingenuity pathway analysis. Univariate and multivariate statistical analysis overlap identified haptoglobin-related protein as a possible marker of IPF when compared to control samples (Area under the curve 0.851, ROC-analysis). LXR/RXR activation and complement activation pathways were enriched in t-test significant proteins and oxidative regulators, complement proteins and protease inhibitors were enriched in PLS-DA significant proteins. Our pilot study points towards aberrations in complement activation and oxidative damage in IPF patients and provides haptoglobin-related protein as a new candidate biomarker of IPF.

摘要

特发性肺纤维化(IPF)是一种病因不明的肺实质疾病,通常发生在老年人中。它是一种慢性进行性疾病,预后不良,诊断主要基于临床。目前,很少有生物标志物可以预测患者的预后或对治疗的反应。除了缺乏标志物外,还需要新型标志物来检测和监测 IPF。我们对 36 个人进行了无标记血浆蛋白质组学分析,其中 17 人被确诊为 IPF。通过火山图、层次聚类、偏最小二乘判别分析(PLS-DA)和Ingenuity 通路分析对蛋白质组学数据进行了分析。单变量和多变量统计分析的重叠表明,与对照样本相比,触珠蛋白相关蛋白是 IPF 的一个潜在标志物(曲线下面积 0.851,ROC 分析)。LXR/RXR 激活和补体激活途径在 t 检验显著蛋白中富集,氧化调节剂、补体蛋白和蛋白酶抑制剂在 PLS-DA 显著蛋白中富集。我们的初步研究表明,IPF 患者存在补体激活和氧化损伤的异常,并提供触珠蛋白相关蛋白作为 IPF 的一个新的候选生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d47d/7211010/c5d10c38b9aa/41598_2020_64759_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验